Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oliceridine (Primary) ; Morphine
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Trevena
  • Most Recent Events

    • 07 Feb 2018 Results of pooled data from six phase 1 and phase 2 trial assessing population pharmacokinetic/pharmacodynamic (PK/PD) model of the PK and PD of oliceridine, were published in the Journal of Clinical Pharmacology.
    • 17 Oct 2016 According to Trevena media release, the company will webcast and present data at the Annual Meeting of the American Society of Anesthesiologists 2016.
    • 14 May 2016 Results of two phase II studies evaluating early reduction in pain intensity, presented at the 35th Annual Scientific Meeting of the American Pain Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top